






# **AGENDA**











# **ÖSSUR'S STRATEGIC FOCUS AREAS**



Life Without Limitations\*

**EFFICIENCY** 

**GROWTH** 

**INNOVATION** 



Oscar Pistorious, the Blade Runner





# **ÖSSUR TODAY**



**EFFICIENCY** 

- Global leader in non-invasive orthopaedics
- Second largest player in the world in prosthetics & bracing and supports

**GROWTH** 

- Positive industry growth drivers
- Favorable market position
- Good margins and strong cash flow

**INNOVATION** 

- Growing through innovation
- Technical leader in the market








# **ÖSSUR – WE ARE A GLOBAL OPERATION**









#### **BRACING AND SUPPORTS – FRAGMENTED MARKET**



#### **BRACING AND SUPPORTS MARKET**

## Products for therapeutic and preventive purposes:

Market size: USD 2,700 m

Market growth: 3-5%

Market share ~7%

Fragmented market

UPPER EXTREMITY SOFT GOODS & SUPPORTS

Spectrag

White the support of the support













## **BRACING AND SUPPORTS PLATFORM**



Life Without Limitations



#### Unload for pain relief and increased mobility









Post-up brace



Rebound® Air Walker

Increase mobility while allowing tissue to heal with functional bracing



Partner to Olympian Oscar Pistorius, the 'Blade Runner'

## **PROSTHETICS – TECHNICAL LEADER**



#### PROSTHETIC MARKET

## Replacement of missing limbs

- Market size: USD 850 m
- Market growth: 3%
- ~ 21% market share
- Consolidated market











# **PROSTHETICS - VALUE THROUGH INNOVATION**



Life Without Limitations

Wood & steel

Mechanical

#### **Current and Future Platforms**









## **HIGHLIGHTS 2012**



MARKET ENVIRONMENT



- Positive outlook for EMEA and Asia
- Impact from RAC audits expected to continue in Americas

STRONG PRODUCT PIPELINE



- Comprehensive bionic platform
- Low activity solutions
- Strong bracing and supports pipeline

CONSOLIDATING MANUFACTURING LOCATIONS



 In-sourcing to our facility in Mexico is according to plan and will result in increased manufacturing efficiency







## **EXTERNAL ENVIRONMENT**



#### **EXTERNAL ENVIRONMENT**

Austerity measures



- Changes in healthcare delivery
- Temporary market shift from high (K3) to lower level active prosthetics products (K2) in the US

Demography



Aging and more active population

Technical development



Continuous technology change and development






## **OUR FOCUS AREAS**




#### **EXTERNAL ENVIRONMENT**

#### ÖSSUR'S STRATEGIC FOCUS AREAS


Austerity measures



Demography



Technical development







#### **OUR STRATEGY**



#### ÖSSUR'S STRATEGIC FOCUS AREAS

#### ÖSSUR'S STRATEGY

#### **Efficiency**

Strive to increase efficiency by:

- operational excellence
- process improvement initiatives
- establishing closer partnership with our customers

Growth

Achieve growth by:

- effectively prove and communicate the outcomes of our products
- increase sales from emerging markets
- leverage on OA opportunities

**Innovation** 

Increase value through innovation by:

- being at the forefront of indication-related innovation in functional healing, osteoarthritis & prosthetics
- improving our customers' mobility





## **GOING FORWARD....**





We generate value for individuals and healthcare systems







2/3 of the Paralympics amputee finalists 2012 ran on Össur feet



#### **MESSAGE TO MARKET 2012 AGM**



2012 Annual General Meeting


- Össur is a stable cash generating company
- Strong balance sheet with rapidly decreasing leverage
- If no material investment opportunities materialize funds will be distributed to shareholders





## STRONG PROFITABILITY AND CASH FLOW





#### Free Cash Flow Yield\* 16% Össur Nordic healthcare companies 14% 13% 12% 12% 10% 8% 6% 6% 6% 4% 5% 2% 0% 2007 2008 2009 2010 2011 2012 YTD

\* **FCF Yield** is free cash flow (excluding acquisitions) divided by market capitalization

Source: Broker's Research





## **STRONG BALANCE SHEET**



USD millions	Q3 2012	Q3 2011
EBITDA	18 19%	20 20%
Cash generated by operations	17 17%	18 18%
Net debt/EBITDA	1.3x	1.6x
Equity Ratio	66%	63%



Stable EBITDA margins and consistent cash conversion levels



Constant deleveraging

USD millions	30.9. 2012	31.12. 2011
Total assets	599	580
Net interest-bearing debt	95	111
Equity	397	365




Low leverage and strong balance sheet





#### **LEVERAGE – INVESTMENT GRADE**









## **ACCESS TO FINANCING**



#### **External environment**

## Össur

**Debt Market** 

- Bank lending in general has remained restricted since 2008
- "Relationship lending"

- Low leverage and open credit lines
- Strong banking partners:



Nordea

**Equity Market** 

- Equity markets volatile
- Difficult to foresee risk appetite of market


- Strong investor base
- Shareholder base broadened by CPH listing in 2009






#### SHAREHOLDERS PORTFOLIO







- Dominated by institutional investors
- Aim to further diversify geographical distribution
- Increased focus on activities with private investors
- Continue to build up the brand and awareness

Increased focus on private investors

Potential dividend payments likely to attract new investors

Source: Össur hf. and VP Oct 2012


ÖSSUR



#### FINANCIAL BRANDING



Focus on activities to attract private investors to improve liquidity and trading performance





## **COMMITTED INVESTMENT CAPACITY IF DISTRIBUTION**



Life Without Limitations\*

	No Distribution	10 M	20 M	30 M	50 M
<b>Equity Ratio</b>	66%	63%	61%	58%	53%
Net debt/EBITDA	1.3x	1.4x	1.5x	1.7x	1.9x
Committed Investment Capacity	USD 70m	USD 60m	USD 50m	USD 40m	USD 20m

Note: Based on Q3 2012 figures





#### **CLOSING REMARKS**



#### **KEY MESSAGE**

- \*\* Strong profitability and cash flow provides solid foundation
- Rapidly decreasing leverage
- Strong balance sheet
- Commitment to raise awareness and trading performance
- Potential dividend policy discussed at 2013 AGM








Life Without Limitations\*

# WE IMPROVE PEOPLE'S MOBILITY





#### **MARKET FUNDAMENTALS**



#### **MARKET DYNAMICS**

- Vascular diseases and diabetes
- Aging population
- Changed lifestyle
- Technological developments

#### **CURRENT MARKET ENVIRONMENT**

- Size: USD 850 million
- Market growth ~ 3%
- Market share ~ 19-21%
- Over 95% of sales reimbursed









#### **DECISSION MAKING UNIT**



Life Without Limitations

	Prescriber	Care Provider	Payer	User
MEMBERS	Rehab physician Surgeon	O&P (97%) Rehab Center (3%)	Insurance Public & Private (95%) Private Pay (5%)	Amputee
INFLUENCE TRENDS	<b>^</b>	<b>\</b>	<b>^</b>	Variable
ÖSSUR COVERAGE	INCREASING FOCUS	STABLE GOOD COVERAGE	INCREASING FOCUS	INCREASING FOCUS

Successfully commercialize innovation by effectively proving and communicating the functional, clinical and economic outcomes of products to the different members of the decission making unit.

# **MARKET OPPORTUNITIES & APPROACH**



	MARKET OPPORTUNITY			OSSUR	GO-TO-MARKET STRATEGY			
	PRODUCT SEGMENT	MARKET TRENDS		OPPORTUNITY	PRODUCT STRATEGY	CUSTOMER FOCUS	MARKETING STRATEGY	OUTCOME
ھ	Low active Vascular / Diabetic Amputee	û	1			MEET THE REQUIREMENTS OF A LARGER CUSTOMER	MEDICAL MARKETING SUPPORTING REIMBURSEMENT	
O&P	Moderate to high active amputee	û	1		PRODUCT LINE EXPANSION PRODUCT DEVELOPMENT TECHNLOGY UPGRADE	BASE: - CPO - PAYER - PRESCRIBER	EXPAND CLINICAL	MARKET SHARE GROWTH PROFITABILITY
	Socket and Interface Solutions	1	<b>î</b>					
	Bionics Solutions	1	î				- USER	MAINTAIN PRICE LEADERSHIP BASED ON INNOVATION

#### **PRODUCT LAUNCHES 2012**



Eight new products and product upgrades introduced during the year.

Main focus on strengthening and broaden the product portfolio







## **AMERICAS – REIMBURSEMENT PRESSURE**



#### **CHARACTERISTICS / MARKET TRENDS**

- Payer audit 个 (pre- & post payment)
- Accelerated consolidation in O&P Services
- Importance ↑ of the physician and payer in the decission making process
- Evidence based care 

  ↑

#### **OPPORTUNITIES**

- Payer submission support
- Clinical partnership
- Mutli-disciplinary support to meet needs of the decission making unit (DMU)
- Clinical evidence & Medical Marketing





#### **EMEA - HEALTHY MARKET**



#### **CHARACTERISTICS / MARKET TRENDS**

- Importance ↑ of the physician and payer in the decission making process
- Regulated process for new product acceptance
- Direct entry of several high-end suppliers

#### **OPPORTUNITIES**

- Mutli-disciplinary support to meet needs of the decission making unit (DMU)
- Clinical evidence & Medical Marketing to support product reimbursement
- Accelerated acceptance of high-end solutions





#### **ASIA – DIVERSE MARKET**



#### **CHARACTERISTICS / MARKET TRENDS**

- Diverse markets
- Mature markets in Japan and Australia
- High need for education, in frastructure and awareness of market participants
- Very small high-end segment

#### **OPPORTUNITIES**


- Focus on China, Korea, SEA countries
- Grow from high-end to medium end market with the right product offering
- Brand building and education efforts essential for success





#### **ÖSSUR VALUE PROPOSITION**





#### **GOING FORWARD.....**



# 3 – 5 YEAR FOCUS

#### ... ÖSSUR WILL GROW PROSTHETICS BY

- \*\* ADDRESSING THE CLINICAL REQUIREMENTS OF THE LOW ACTIVE AMPUTEE
- \*\* ANSWERING TO THE REQUIREMENTS OF THE DMU
  THROUGH MEDICAL MARKETING AND CLINICAL
  PARTNERSHIP
- PURSUING EXPANSION INTO EMERGING MARKETS








Life Without Limitations\*

### WE IMPROVE PEOPLE'S MOBILITY





#### **R&D VISION**



Life Without Limitations\*

#### **R&D VISION:**

To be the industry leader that creates the future through clinically validated innovative solutions







#### THE WAY TO OUR R&D VISION



With indication based approach and building comprehensive product lines, Össur will transform the manner in which people's mobility is improved

Indication based approach

Comprehensive product lines


Clinically validated innovative solutions





ÖSSUR








#### **INNOVATION - INDICATION BASED APPROACH**





" Design is how it works"





# WE NEED TO UNDERSTAND THE CLINICAL PATHWAY DIABETIC/AMPUTATION



# CHANCE OF RECOVERY: AMPUTATION AND REGAINED MOBILITY: Compression therapy Diabetic walker Post -op solution Mechanical products Proprio


- Where are unsolved medical problems?
- Do we already have products to solve the medical problem?
- Where can we use innovative technology to solve the medical problem?





ÖSSUR







#### **PROSTHETICS – TECHNICAL LEADER**




Life Without Limitations\*

#### Increase mobility for amputees

#### **Epidemiology and medical trends:**

- Aging population
- Increased diabetics
- Increased demand for functionality







#### **LOW ACTIVITY SOLUTIONS**



#### The Balance Line:



Balance knee and the Flex-Foot balance were designed to offer less active users security and stability

- Increased demand for low-active products because of aging and more active population
- Increased clinical need and reimbursement challenges
- Continue to design an innovative approach for low active amputees








#### **BIONICS PLATFORM - WORLD'S FIRST BIONIC LEG**



Life Without Limitations\*






#### SYMBIONIC<sup>TM</sup> LEG

Seamlessly unites the proven capabilities of RHEO KNEE® and PROPRIO FOOT®















#### **FUNCTIONAL HEALING**



#### Increase mobility while allowing tissue to heal with functional bracing



#### **HEALING PROCESS:**







#### **EXAMPLE OF CLINICAL PATHWAY FOR THE KNEE**



PREVENTION FUNCTIONAL HEALING CHRONIC






Ligament

Osteochondrallesions



Total knee replacement







#### **ACHILLES TENDON RUPTURES - WALKERS INSTEAD OF CAST**



## Cast seen as the golden standard in Europe whereas walkers more frequently used in the US

#### **ACHILLES TENDON RUPTURES**










ÖSSUR









#### **OSTEOARTHRITIS**



#### Unload or immobilize for pain relief and increased mobility







#### **OSTEOARTHRITIS - ATTRACTIVE MARKET**



Size:

Est. 5% of population have knee OA

#### TKR:

Tremendous growth in total knee replacements

Cost:

1-2.5% of GDP

Driver:

Aging and active population

Potential:

#4 leading cause of disability 2020





#### **ALTERNATIVE TREATMENT TO OSTEOARTHRITIS**




The Unloader One Knee Brace is a non-invasive, economical treatment option for osteoarthritis, proven to reduce pain and improve mobility





Clinically proven: Reported change in medication








Steadman Philippon Unloader One research













#### **GOING FORWARD.....**



# KEY MESSAGE

- \* Key innovation drivers: epidemiology, medical trends and clinical pathways
- Effectively prove and communicate clinical outcome
- Innovation approach will be indication based and user driven

**R&D Vision:** To be the industry leader that creates the future through clinically validated innovative solutions







Life Without Limitations\*

### WE IMPROVE PEOPLE'S MOBILITY

